Phaseline

Targets › PKD1

PKD1 (Polycystin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Nov 2028.

Component of a heteromeric calcium-permeable ion channel formed by PKD1 and PKD2 that is activated by interaction between PKD1 and a Wnt family member, such as WNT3A and WNT9B. Both PKD1 and PKD2 are required for channel activity. Involved in renal tubulogenesis. (UniProt, P98161)

Open in Phaseline: the race on PKD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PYC TherapeuticsPYC-003
Peptide-phosphorodiamidate morpholino oligonucleotide conjugate targeting PKD1
PKD1Phase 1Autosomal Dominant Polycystic Kidney Disease (ADPKD)Nov 2028

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD) (1)

Modalities

small molecule (1)

Companies

PYC Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.